Tourmaline Bio Profit Margin

Tourmaline Bio's profit margin stands at -221185.0% as of June 2025. That is below the Healthcare sector average of 19.13%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Tourmaline Bio sits lower the Healthcare benchmark (19.13%) with a profit margin of -221185.0%. That is roughly 1156242.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -221185.0% for Tourmaline Bio means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Tourmaline Bio's profit margin evolved across reporting periods, while the comparison chart places TRML next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, profit margin is commonly used to spot outliers. Tourmaline Bio's reading of -221185.0% (sector avg 19.13%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.